Home › Research › Treatments
Safety of Lecanemab After 6‐Month Treatment in the DIAN‐TU‐001 Trial
Jin Zhou, Erica M. Andreozzi, Jorge J. Llibre‐Guerra, David B. Clifford, David Li, Guoqiao Wang, Lon S. S. Schneider, Eric McDade et al.. Alzheimer s & Dementia, 2025-12-01
Topic: Risk, prevention and care in population studies
Plain-language summary
Lecanemab was generally well-tolerated during the 6-month lecanemab-only treatment period. Overall, 80.4% of the 97 participants enrolled and treated experienced an adverse event. The most common AEs were ARIA-H (26.8%), headache (25.8%), ARIA-E (20.6%), and infusion-related reactions (11.3%). The incidence of ARIA-E was 20.6% and the incidence of ARIA-H was 26.8%. The rate of symptomatic ARIA-E was 4.1% and symptomatic ARIA-H was 1.0%. ARIA-E most commonly occurred within the first 3 months of treatment (80.0%) and resolved within 4 months (75%). There were no cases of symptomatic isolated ARIA-H, no intracerebral hemorrhage (>10 mm), and 2 (2.06%) individuals who experienced ARIA leading to lecanemab withdrawal. The majority AEs were mild or moderate, with a total of 6 (6.19%) participants experiencing a serious AE. Lecanemab was generally well-tolerated. The most common adverse events of lecanemab in the DIAD population were ARIA-H, headache, ARIA-E, and infusion-related reactions. DIAD population may have a higher rate of cerebral amyloid angiopathy with ARIA rates between heterozygotes and homozygotes in sporadic AD.
What this study adds
Evidence grade: High
The record lists 97 participants. In the DIAN-TU-001 trial, lecanemab was generally well tolerated over 6 months among 97 treated participants, with ARIA-H in 26.8 percent, headache in 25.8 percent, ARIA-E in 20.6 percent, and infusion-related reactions in 11.3 percent. Reported effect size: 80.4%; 26.8%; 25.8%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Zhou, J., Andreozzi, E. M., Llibre‐Guerra, J. J., Clifford, D. B., Li, D., Wang, G., et al. (2025). Safety of Lecanemab After 6‐Month Treatment in the DIAN‐TU‐001 Trial. Alzheimer s & Dementia. https://doi.org/10.1002/alz70859_105304
Vancouver
Zhou J, Andreozzi EM, Llibre‐Guerra JJ, Clifford DB, Li D, Wang G, et al. Safety of Lecanemab After 6‐Month Treatment in the DIAN‐TU‐001 Trial. Alzheimer s & Dementia. 2025. doi:10.1002/alz70859_105304. PMID: 41447712.
BibTeX
@article{zhou2025-41447712,
author = {Zhou, Jin and Andreozzi, Erica M. and Llibre‐Guerra, Jorge J. and Clifford, David B. and Li, David and Wang, Guoqiao and Schneider, Lon S. S. and McDade, Eric and others},
title = {{Safety of Lecanemab After 6‐Month Treatment in the DIAN‐TU‐001 Trial}},
journal = {Alzheimer s \& Dementia},
year = {2025},
doi = {10.1002/alz70859_105304},
pmid = {41447712},
url = {https://doi.org/10.1002/alz70859_105304}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Lecanemab was generally well-tolerated during the 6-month lecanemab-only treatment period.
- Overall, 80.4% of the 97 participants enrolled and treated experienced an adverse event.
- The most common AEs were ARIA-H (26.8%), headache (25.8%), ARIA-E (20.6%), and infusion-related reactions (11.3%).
- The incidence of ARIA-E was 20.6% and the incidence of ARIA-H was 26.8%.
- The rate of symptomatic ARIA-E was 4.1% and symptomatic ARIA-H was 1.0%.
Why it matters
In the DIAN-TU-001 trial, lecanemab was generally well tolerated over 6 months among 97 treated participants, with ARIA-H in 26.8 percent, headache in 25.8 percent, ARIA-E in 20.6 percent, and infusion-related reactions in 11.3 percent. Most adverse events were mild or moderate, and 6 participants had a serious adverse event.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Participants97
- Effect size80.4%; 26.8%; 25.8%
- Evidence strengthHigh
How this study scored 49/100
Published in a peer-reviewed journal. Scored zero for study design and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer s & Dementia) |
| Journal's citation record | 2 / 4 | Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 1 / 4 | 97 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 2 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.7 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 2 / 6 | Cited 1.1× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 1 other studies in this library |
| Still being cited | 0 / 4 | Cited 2 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Randall John Bateman: h-index 101 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | Washington University in St. Louis: institution h-index 1,962 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 3 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41447712) |
| Free to read | 2 / 2 | Free to read |
| Total | 49 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1002/alz70859_105304
- PubMed: 41447712
- Original source →
- Free full text: Alzheimer s & Dementia →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Later studies that cite this one
1 study in the alzhub library lists this one in its references.
Related studies in Treatments from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.